IL6 and colitis: The results showed that miR-155 antagomir improved the disease activity index and led to a decrease in Th17 cells and a concomitant downregulation of the cytokines IL-17A and IL-6, but an increase in Tregs, IL-10, and TGF-B1 in the mesenteric lymph nodes, suggesting that maintaining the balance between Th17 and Treg cells is a means to attenuate colitis [79].